Heidelberg Pharma Advances HDP-101 to Phase IIa in Multiple Myeloma

Company Heidelberg Pharma AG Event Type Clinical development and corporate financing update Modality Amanitin-based antibody-drug conjugate (ATAC platform) Asset HDP-101 (pamlectabart tismanitin) Target BCMA Disease Area Relapsed or refractory multiple myeloma Summary Heidelberg Pharma disclosed in its July 15 half-year report that the Phase I…